Published in Adv Cancer Res on January 01, 2004
Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol (2014) 2.23
Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol (2009) 2.20
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer (2008) 1.13
Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res (2013) 1.13
Stroma-epithelium crosstalk in prostate cancer. Asian J Androl (2008) 1.07
Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer (2006) 1.07
A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol (2009) 1.06
RasGRP Ras guanine nucleotide exchange factors in cancer. Front Biol (Beijing) (2013) 1.04
RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype. Cancer Res (2010) 1.04
β4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest (2013) 1.03
Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One (2013) 1.03
Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer (2010) 1.03
Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases. Cancer Metastasis Rev (2014) 1.00
RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer (2014) 0.93
Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev (2014) 0.92
KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer. BMC Cancer (2012) 0.92
Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases. Int J Biol Sci (2014) 0.87
Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem (2012) 0.87
Trading in your spindles for blebs: the amoeboid tumor cell phenotype in prostate cancer. Asian J Androl (2014) 0.83
Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol (2005) 0.82
High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. Exp Ther Med (2012) 0.82
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer. Oncotarget (2016) 0.79
Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer. Adv Ther (2013) 0.79
Met in urological cancers. Cancers (Basel) (2014) 0.77
Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures. Oncotarget (2016) 0.75
Simultaneous stretching and contraction of stress fibers in vivo. Mol Biol Cell (2004) 2.12
Stromal-epithelial interaction in prostate cancer progression. Clin Genitourin Cancer (2006) 1.33
Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther (2005) 1.07
Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer (2006) 1.07
Changes in gap junctional connexin isoforms during prostate cancer progression. Prostate (2006) 0.91
[Increase of syphilis among men who have sex with men]. Lakartidningen (2009) 0.75